The estimated Net Worth of Seth Herbst is at least 252 千$ dollars as of 2 January 2024. Seth Herbst owns over 27,174 units of Dyadic International stock worth over 165,218$ and over the last 5 years he sold DYAI stock worth over 0$. In addition, he makes 87,000$ as Independent Director at Dyadic International.
Sign up
Seth Herbst DYAI stock SEC Form 4 insiders trading
Seth has made over 3 trades of the Dyadic International stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 27,174 units of DYAI stock worth 33,968$ on 2 January 2024.
The largest trade he's ever made was exercising 50,000 units of Dyadic International stock on 29 January 2021 worth over 96,500$. On average, Seth trades about 12,772 units every 134 days since 2020. As of 2 January 2024 he still owns at least 132,174 units of Dyadic International stock.
You can see the complete history of Seth Herbst stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Seth Herbst biography
Dr. Seth J. Herbst M.D. serves as Independent Director of the Company. Seth J. Herbst, MD has been on the Board since June 2008 and is a board-certified obstetrician/gynecologist who is also board certified in advanced laparoscopic and minimally invasive gynecologic surgery. Dr. Herbst is the founder and President of the Institute for Women’s Health and Body (“IWHB”) in May of 1997, an OB/GYN practice with multiple locations in Palm Beach County, Florida. He is the co-founder of Visions Clinical Research since 1999, which performs medical and surgical clinical trials throughout the United States. Dr. Herbst founded IWHB of Palm Beach, a Physician Management Group that currently employs 43 providers, which he actively directs the operations on a daily basis. Dr. Herbst is a member of the board of directors of Palms West Hospital in Loxahatchee, Florida. Dr. Herbst is also a consultant for multiple medical device companies in the United States and a member of medical advisory boards for these and other companies. He received his B.S. degree from American University in 1978 and his medical degree from Universidad del Noreste School of Medicine in Tampico, Mexico in 1983. Dr. Herbst completed his OB/GYN residency and was Chief Resident at Long Island College Hospital in Brooklyn, New York.
What is the salary of Seth Herbst?
As the Independent Director of Dyadic International, the total compensation of Seth Herbst at Dyadic International is 87,000$. There are 10 executives at Dyadic International getting paid more, with Mark Emalfarb having the highest compensation of 1,074,050$.
How old is Seth Herbst?
Seth Herbst is 62, he's been the Independent Director of Dyadic International since 2008. There are 7 older and 3 younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.
What's Seth Herbst's mailing address?
Seth's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Insiders trading at Dyadic International
Over the last 6 years, insiders at Dyadic International have traded over 118,246,658,250$ worth of Dyadic International stock and bought 27,000 units worth 100,230$ . The most active insiders traders include Mark A Emalfarb、Ronen Tchelet、Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of 54,365$. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth 18,751$.
What does Dyadic International do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
What does Dyadic International's logo look like?
Complete history of Seth Herbst stock trades at Dyadic International
Dyadic International executives and stock owners
Dyadic International executives and other stock owners filed with the SEC include:
-
Mark Emalfarb,
President, Chief Executive Officer, Director -
Mark A. Emalfarb,
Founder, CEO, Pres & Director -
Matthew Jones,
Managing Director - Business Development and Licensing -
Ping Rawson,
Chief Financial Officer, Chief Accounting Officer -
Matthew S. Jones,
Managing Director of Bus. Devel. & Licensing -
Ronen Tchelet,
Vice President of Research and Business Development -
Dr. Ronen Tchelet Ph.D.,
VP of Research & Bus. Devel. -
Jack Kaye,
Independent Director -
Arindam Bose,
Independent Director -
Michael Tarnok,
Independent Chairman of the Board -
Seth Herbst,
Independent Director -
Barry Buckland,
Independent Director -
Ana Gómez Rodriguez,
Sec. of the Board -
Joseph P. Hazelton,
Chief Bus. Officer -
Patrick K. Lucy,
Director -
Trust Under Agreement Dated...,
10% owner -
Joseph P Hazelton,
Chief Business Officer